Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | PPARG | P37231 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13186474 | 0.78 | MAPT (0.60) | NPC1RAB9AMEN1KMT2AEPHX2 | |
| SCHEMBL5331526 | 0.75 | MMP13 (0.74) | NPC1RAB9AMEN1KMT2AEPHX2 | |
| SCHEMBL2526264 | 0.74 | NPC1 (0.83) | NPC1RAB9APPARGMEN1KMT2A | |
| SCHEMBL2918147 | 0.74 | NPC1 (0.83) | NPC1RAB9APPARGMEN1KMT2A | |
| SCHEMBL5335143 | 0.74 | CYP1A2 (0.66) | NPC1RAB9APPARGNR1H4L3MBTL1 | |
| SCHEMBL5335138 | 0.74 | CYP1A2 (0.66) | NPC1RAB9APPARGNR1H4L3MBTL1 | |
| SCHEMBL5331977 | 0.73 | MMP13 (0.76) | NPC1RAB9AMEN1KMT2AEPHX2 | |
| SCHEMBL11761142 | 0.73 | NPC1 (0.82) | NPC1RAB9APPARGMEN1KMT2A | |
| SCHEMBL9416606 | 0.73 | NPC1 (0.82) | NPC1RAB9APPARGMEN1KMT2A | |
| SCHEMBL23984534 | 0.72 | HPGD (0.67) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198914-B2 | Methods and compositions for modulating RAD51 and homologous recombination | THE UNIVERSITY OF CHICAGO (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140142103-A1 | Methods and Compositions for Modulating Rad51 and Homologous Recombination | THE UNIVERSITY OF CHICAGO (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142103-A1 | Methods and Compositions for Modulating Rad51 and Homologous Recombination | RAD51, MRE11, RAD50 | NPC1 4834/4885RAB9A 2759/4885PPARG 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.